Why We Invested In Totient aka How AI Can Help Us Produce Drugs Against Cancer And Covid

On Sep 10, Totient, an AI-driven drug discovery company, emerged from stealth with the announcement of a key partnership with Ginkgo Bioworks to rapidly identify neutralizing antibodies against COVID-19. Totient has raised more than $10M in seed capital from Tau Ventures and an exceptional mix of other tech and life science investors. Our conviction in Totient is rooted in (1) the ambitious vision, shared by (2) a team which is both scientifically and commercially experienced, (3) and early platform validation. This post is focused specifically on Totient but reflects how we at Tau think about seed-stage investments broadly. 1) Vision…...